{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:05:49Z","timestamp":1693631149160},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":640,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1002\/jcph.228","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T12:02:39Z","timestamp":1384171359000},"page":"503-512","source":"Crossref","is-referenced-by-count":4,"title":["Similar Relationship Between the Time Course of Bone Mineral Density Improvement and Vertebral Fracture Risk Reduction With Denosumab Treatment in Postmenopausal Osteoporosis and Prostate Cancer Patients on Androgen Deprivation Therapy"],"prefix":"10.1002","volume":"54","author":[{"given":"Juan Jose","family":"P\u00e9rez Ruixo","sequence":"first","affiliation":[{"name":"Amgen, Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Zheng","sequence":"additional","affiliation":[{"name":"Amgen, Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap W.","family":"Mandema","sequence":"additional","affiliation":[{"name":"Quantitative Solutions; Menlo Park CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"10.1002\/jcph.228-BIB0001|jcph228-cit-0001","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"Br Med J."},{"key":"10.1002\/jcph.228-BIB0002|jcph228-cit-0002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med."},{"key":"10.1002\/jcph.228-BIB0003|jcph228-cit-0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1002\/jcph.228-BIB0004|jcph228-cit-0004","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/jc.2006-2758","article-title":"Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate","volume":"92","author":"Bruyere","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1002\/jcph.228-BIB0005|jcph228-cit-0005","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","article-title":"Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis","volume":"21","author":"Chen","year":"2006","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0006|jcph228-cit-0006","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/sim.984","article-title":"A method to assess the proportion of treatment effect explained by a surrogate endpoint","volume":"20","author":"Li","year":"2001","journal-title":"Stat Med."},{"key":"10.1002\/jcph.228-BIB0007|jcph228-cit-0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0008|jcph228-cit-0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom."},{"key":"10.1002\/jcph.228-BIB0009|jcph228-cit-0009","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5\u2009mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Jacques","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0010|jcph228-cit-0010","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med."},{"issue":"12","key":"10.1002\/jcph.228-BIB0011|jcph228-cit-0011","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"10.1002\/jcph.228-BIB0012|jcph228-cit-0012","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1002\/jcph.228-BIB0013|jcph228-cit-0013","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0014|jcph228-cit-0014","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1002\/jcph.228-BIB0015|jcph228-cit-0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1002\/jcph.228-BIB0016|jcph228-cit-0016","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0017|jcph228-cit-0017","unstructured":"Zheng J Mandema JW Perez Ruixo JJ. Model-based meta-analysis for comparative efficacy of osteoporosis. Presented at American Society of Clinical Pharmacology, Maryland, March 12-17, 2012"},{"key":"10.1002\/jcph.228-BIB0018|jcph228-cit-0018","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1002\/jcph.228-BIB0019|jcph228-cit-0019","first-page":"S160","article-title":"Changes in bone mineral density as a predictor of vertebral fracture efficacy with ibandronate: results from a phase III fracture study","author":"Wasnich","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0020|jcph228-cit-0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bone.2007.06.010","article-title":"Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy","volume":"41","author":"Seeman","year":"2007","journal-title":"Bone."},{"key":"10.1002\/jcph.228-BIB0021|jcph228-cit-0021","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0022|jcph228-cit-0022","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1002\/jcph.228-BIB0023|jcph228-cit-0023","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res."},{"key":"10.1002\/jcph.228-BIB0024|jcph228-cit-0024","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol."},{"key":"10.1002\/jcph.228-BIB0025|jcph228-cit-0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell."},{"key":"10.1002\/jcph.228-BIB0026|jcph228-cit-0026","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":"Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology."},{"key":"10.1002\/jcph.228-BIB0027|jcph228-cit-0027","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/jcph.228-BIB0028|jcph228-cit-0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1749-6632.2012.06674.x","article-title":"The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction","volume":"1263","author":"Goessl","year":"2012","journal-title":"Ann NY Acad Sci."},{"key":"10.1002\/jcph.228-BIB0029|jcph228-cit-0029","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"10.1002\/jcph.228-BIB0030|jcph228-cit-0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","article-title":"Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study","volume":"16","author":"Bolognese","year":"2013","journal-title":"J Clin Densitom."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.228\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:00Z","timestamp":1657803780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.228"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.228","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,30]]}}}